肝病药物市场按疾病类型、治疗类型、给药途径、药物类别、最终用户和分销管道划分－2025-2030 年全球预测

预计肝病药物市场规模2024年将达187.6亿美元，2025年将达202.6亿美元，2030年将达300亿美元，复合年增长率为8.13%。

主要市场统计数据
基准年2024年	187.6亿美元
预计2025年	202.6亿美元
预测年份 2030	300亿美元
复合年增长率（%）	8.13%

深入调查应对肝病挑战的治疗策略的现状和未来潜力

肝病的盛行率和复杂性日益增加，亟需开发能有效应对慢性和急性肝病的创新治疗策略。传统治疗方法依赖抗病毒药物和支持治疗，但近年来，对纤维化机制、免疫调节和细胞再生的深刻洞察正在推动重大转变。本简介探讨了跨学科研究、尖端生物技术平台和以患者为中心的框架如何融合，重塑治疗格局。

最近的科学突破和以患者为中心的创新如何重新定义肝病治疗的治疗方法和结果

过去十年，科学突破催化了人们对肝病理解和管理方式的变革性转变。基因疗法的创新释放了改变潜在遗传易感性的潜力，而细胞和再生疗法的进步则提供了恢復肝功能的策略。同时，微生物组调节疗法的引入正在重新定义肝病治疗模式，透过利用肠肝轴沟通来抑制发炎和纤维化。

评估 2025 年美国关税对肝病药物研发、供应链和可近性的深远影响

2025年美国关税的实施，为全球肝病治疗药物供应链带来了新的复杂性。包括用于基因和细胞治疗的专用生物成分和试剂在内的国际原料正面临越来越大的成本压力。随着製造成本的上升，相关人员面临着在不影响品质或可及性的情况下保持有竞争力的价格的挑战。

透过对疾病类型、治疗方式、给药途径、药物类别、使用者偏好和分销管道进行多维细分，发现关键见解

准确了解患者亚群对于制定肝病治疗性介入至关重要。基于疾病类型的细分涵盖了从酒精性肝病到慢性病毒感染疾病（例如乙肝和丙肝）、肝细胞癌和胆管​​癌的亚型，以及日益频谱的非酒精性肝病等所有疾病类型。每种疾病类型都有其独特的病理学机制和临床管理考虑因素。

检验影响美洲、中东和非洲以及亚太地区肝病治疗创新、取得和采用的区域动态和独特促进要素

区域动态对肝病药物的采用、开发和可近性有着巨大的影响。在美洲，强大的法律规范和成熟的临床试验网络正在加速先进生技药品和基因疗法的普及。医疗保健系统日益重视基于价值的医疗方案，这推动了对能够比现有标准疗法具有明显临床和经济效益的疗法的需求。

介绍透过研究和合作推动全球肝病治疗领域创新、协作和策略成长的最具影响力的组织

肝病治疗格局正在由主要企业塑造，他们透过广泛的研究管道、策略伙伴关係和有针对性的收购推动创新，而新兴生物技术公司则专注于高影响力的利基领域，例如遗传代谢疾病的基因校正和肝癌的个人化免疫疗法。

产业领导者面临的策略挑战是如何利用新兴机会、降低风险并推动肝病药物开发和交付的可持续成长

产业领导者必须果断行动，抓住肝病治疗领域的新兴机会。首先，投资灵活的生产平台可以缓解供应链中断，并提高对关税造成的成本压力的应对力。各机构应评估能够透过风险共用模式共同开发细胞和基因疗法的伙伴关係，以在控製成本的同时加速临床进展。

综合主要观察和策略考虑，强调创新治疗方法、协作努力和政策考量在推进肝病治疗中的关键作用。

本执行摘要概述了影响肝病治疗当前和未来的关键趋势、它们对关税、细分细微差别、区域驱动因素和关键组织策略的影响。先进的生物平台、基因编辑技术和以患者为中心的交付模式的融合正在重塑从病毒性肝炎到复杂肝细胞癌的治疗可能性。

目录

第一章 引言

第二章 分析方法

第三章执行摘要

第四章 市场概述

第五章市场动态

• 引入针对遗传性肝病的基因编辑疗法，并提高递送载体的安全性
• 肝病发生率上升推动治疗需求
• 整合人工智慧平台优化非酒精性脂肪性肝炎临床试验
• 新型调控途径支持以细胞为基础的肝功能衰竭和肝硬化治疗创新
• 以患者为中心的远端监控解决方案的增长，用于早期发现和管理肝臟併发症
• 创业投资激增推动早期肝臟治疗
• 製药和生物技术公司合作加速开发潜在的肝纤维化治疗方法
• 晚期肝细胞癌的小分子和生物製药联合治疗的发展
• 政府措施和公众意识促进肝病的早期发现
• 使用多组体学物标记开发个人化医疗管道以预测患者在 NASH 试验中的反应

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章：美国关税的累积影响（2025年）

第 8 章：依疾病类型分類的肝病药物市场

• 酒精性肝臟疾病
• B型肝炎
• C型肝炎
• 肝癌
  • 胆管癌
  • 肝细胞癌
• 非酒精性脂肪肝

第九章肝病药物市场（依治疗类型）

• 生物免疫治疗
• 基于细胞的再生疗法
• 基因治疗
• 微生物组调节疗法
• 小分子药物

第 10 章肝病药物市场（依给药途径）

• 静脉
• 口服
• 皮下

第 11 章：肝病药物市场（依药物类别）

• 抗纤维化
  • Pirfenidone
  • 辛妥珠单抗
• 抗病毒药物
  • 干扰素
  • NS5A抑制剂
  • NS5B聚合酵素抑制剂
  • 核苷酸/核苷类似物
  • 蛋白酶抑制剂
• 化疗
• 皮质类固醇
• 免疫抑制剂
• 单株抗体

第十二章肝病药物市场（依最终用户）

• 诊所
• 居家医疗
• 医院

第十三章肝病药物市场（依通路）

• 医院药房
• 网路药局
• 零售药局

14.美洲肝病药物市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

15.欧洲、中东和非洲肝病药物市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

16.亚太地区肝病药物市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十七章竞争格局

• 2024年市场占有率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • Intercept Pharmaceuticals, Inc. by Alfasigma SpA
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • AstraZeneca PLC
  • CH Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • Genfit SA
  • Astellas Pharma Inc.
  • Moderna, Inc.
  • Alnylam Pharmaceuticals, Inc.

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

The Liver Diseases Therapeutics Market was valued at USD 18.76 billion in 2024 and is projected to grow to USD 20.26 billion in 2025, with a CAGR of 8.13%, reaching USD 30.00 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 18.76 billion
Estimated Year [2025]	USD 20.26 billion
Forecast Year [2030]	USD 30.00 billion
CAGR (%)	8.13%

An In-Depth Exploration of the Current State and Future Potential in Therapeutic Strategies for Addressing Liver Disease Challenges

The escalating prevalence and complexity of liver diseases present an urgent imperative for innovative therapeutic strategies that can effectively address the spectrum of chronic and acute hepatic conditions. While traditional approaches have long relied on antiviral agents and supportive care, recent years have witnessed a profound shift driven by deeper insights into fibrotic mechanisms, immune modulation, and cellular regeneration. This introduction explores how multidisciplinary research, advanced biotechnology platforms, and patient-centered frameworks are converging to reshape the therapeutic landscape.

Throughout this report, attention is devoted to understanding how novel platforms-ranging from next-generation biologic immunotherapies to the precision of gene editing-are targeting pathophysiological pathways with unprecedented specificity. As the pipeline expands, comprehensive analyses will examine factors such as the evolving regulatory environment, supply chain resilience in light of new tariff policies, and synergies between established pharmaceutical players and emerging biotech innovators.

By presenting an integrated overview of strategic dynamics and emerging opportunities, this section sets the stage for a deeper exploration of transformative shifts, tariff implications, segmentation insights, and regional drivers that collectively inform strategic decision-making in the field of liver disease therapeutics.

How Recent Scientific Breakthroughs Coupled with Patient-Centric Innovations Are Redefining Therapeutic Approaches and Outcomes in Liver Disease Care

Over the past decade, scientific breakthroughs have catalyzed transformative shifts in how liver diseases are understood and managed. Innovations in gene therapy are unlocking the potential to correct underlying genetic predispositions, while advancements in cell-based and regenerative therapies are offering strategies to restore hepatic function. Concurrently, the introduction of microbiome-modulating therapies is redefining paradigms by harnessing gut-liver axis communications to attenuate inflammation and fibrosis.

In addition to technological leaps, patient-centric approaches are gaining prominence. Personalized immunotherapeutic regimens, informed by individual biomarker profiles, are enhancing efficacy and reducing adverse events. Furthermore, strategic alliances between pharmaceutical companies and academic research centers are accelerating translational efforts, resulting in streamlined clinical development pathways and more robust evidence generation.

As a result of these converging forces, liver disease therapeutics are transitioning from reactive symptom management toward proactive disease modification and potential reversal of hepatic damage. This section examines the catalysts driving this evolution, including shifts in regulatory expectations, expanded access programs, and the rising importance of real-world evidence in shaping therapeutic value propositions.

Assessing the Far-Reaching Consequences of the 2025 United States Tariff Measures on the Development, Supply Chains, and Accessibility of Liver Disease Treatments

The introduction of United States tariff measures in 2025 has introduced new complexities into the global supply chains for therapeutic agents targeting liver conditions. Raw materials sourced from overseas, including specialized biologic components and reagents for gene and cell therapies, have experienced increased cost pressures. As manufacturing expenses rise, stakeholders face challenges in maintaining competitive pricing structures without compromising quality or accessibility.

Moreover, these tariffs have prompted companies to reassess their sourcing strategies, with some opting to diversify suppliers or establish local production capabilities. Such shifts carry implications for production timelines, regulatory compliance, and inventory management. In parallel, research collaborations that depend on cross-border exchanges of proprietary materials and technologies are navigating a more intricate tariff landscape that demands enhanced logistical coordination.

Despite these headwinds, the tariff environment has also spurred greater investment in domestic manufacturing infrastructure and encouraged the exploration of alternative raw-material platforms. By evaluating the cumulative impact of these measures, industry leaders can develop resilient strategies that safeguard continuity of supply, optimize cost structures, and ensure ongoing patient access to critical liver disease therapies.

Unveiling Critical Insights from Multi-Dimensional Segmentation Across Disease Types, Therapeutic Modalities, Administration Routes, Drug Classes, User Settings, and Distribution Channels

A nuanced understanding of patient subpopulations is foundational to tailoring therapeutic interventions for liver diseases. Segmentation based on disease type captures the full spectrum from Alcoholic Liver Disease to chronic viral infections such as Hepatitis B and Hepatitis C, as well as hepatocellular and cholangiocarcinoma subtypes of liver cancer and the increasingly prevalent Non-Alcoholic Liver Disease. Each of these categories presents unique pathophysiological mechanisms and clinical management considerations.

Equally critical is analyzing the therapeutic modalities under investigation. Biologic immunotherapies are leveraging checkpoint inhibition and cytokine modulation, while cell-based and regenerative approaches seek to replace or repair damaged hepatic tissue. Gene therapies are poised to address inherited metabolic disorders, and microbiome-modulating interventions aim to restore gut-liver axis equilibrium. Meanwhile, the continued refinement of small-molecule compounds ensures a diverse arsenal against fibrotic and inflammatory pathways.

Routes of administration influence both patient adherence and pharmacokinetic profiles, with intravenous infusions facilitating high-dose or acute interventions, oral formulations providing convenience for chronic regimens, and subcutaneous injections offering a middle ground between efficacy and ease of use. Alongside these considerations, drug classes such as antifibrotic agents-encompassing molecules like pirfenidone and simtuzumab-and a range of antiviral compounds, including interferons and NS5A inhibitors, each play distinct roles in interrupting disease progression.

Finally, understanding the contexts in which therapies are delivered is essential. End users span from specialized clinics to home care settings and hospital environments, necessitating flexible treatment protocols and support infrastructures. Distribution channels, whether via hospital pharmacies, online dispensaries, or retail outlets, further shape access dynamics and patient experiences.

Examining Regional Dynamics and Unique Drivers Across the Americas, Europe Middle East & Africa, and Asia-Pacific That Influence Therapeutic Innovation, Access, and Adoption in Liver Disease Care

Regional dynamics exert a powerful influence on the adoption, development, and accessibility of liver disease therapies. In the Americas, strong regulatory frameworks and established clinical trial networks have accelerated the introduction of advanced biologics and gene therapies. Healthcare systems are increasingly focused on value-based care initiatives, driving demand for treatments that can demonstrate clear clinical and economic benefits over existing standards.

Europe, the Middle East, and Africa present a diverse landscape shaped by varying healthcare infrastructures and policy environments. Within this region, collaborative consortia have facilitated cross-border clinical studies, while multinational reimbursement pathways continue to evolve. Emerging economies are investing in expanded diagnostic and treatment capacities, creating new opportunities for therapies targeting both viral hepatitis and non-alcoholic steatohepatitis.

In Asia-Pacific, robust government support for research and development, combined with high prevalence rates of both viral and metabolic liver diseases, has cultivated a fertile environment for innovation. Local biotech enterprises are partnering with global pharmaceutical leaders to co-develop novel interventions, and patient access programs are adapting to the unique socioeconomic conditions across the region.

Together, these regional insights underscore the importance of tailored strategies that align regulatory, economic, and healthcare delivery considerations with the specific needs and drivers of each market.

Profiling the Most Influential Organizations Driving Innovation, Partnerships, and Strategic Growth in the Global Liver Disease Therapeutics Arena Through Research and Collaborations

The liver disease therapeutics landscape is shaped by a constellation of leading companies that drive innovation through expansive research pipelines, strategic partnerships, and targeted acquisitions. Established pharmaceutical entities continue to leverage their global development capabilities to advance large-scale clinical programs, while emerging biotechs are focusing on high-impact niches such as gene correction for inherited metabolic disorders and personalized immunotherapies for liver cancer.

Collaborative networks between academic institutions and industry players are increasingly prolific, enabling the rapid translation of preclinical discoveries into early-phase clinical trials. In parallel, alliances with contract manufacturing organizations are enhancing production scalability for complex biologics and cell therapies. The pursuit of orphan drug designations and accelerated approval pathways further illustrates how companies are navigating regulatory landscapes to bring breakthrough treatments to patients more swiftly.

Innovation is complemented by strategic investments in advanced manufacturing technologies, including closed-system bioreactors and automated cell processing, which collectively reduce production bottlenecks and improve batch consistency. Concurrently, players across the spectrum are exploring digital health integrations-from remote patient monitoring to AI-driven biomarker analysis-that have the potential to refine clinical development and broaden access.

Through a combination of in-house research excellence, external collaborations, and forward-looking technology adoption, these key companies are at the forefront of transforming liver disease treatment paradigms.

Strategic Imperatives for Industry Leaders to Capitalize on Emerging Opportunities, Mitigate Risks, and Foster Sustainable Growth in Liver Disease Therapeutic Development and Delivery

Industry leaders must act decisively to capitalize on emerging opportunities within liver disease therapeutics. First, investing in flexible manufacturing platforms will mitigate supply chain disruptions and enhance responsiveness to tariff-induced cost pressures, thereby safeguarding uninterrupted patient access. Organizations should evaluate partnerships that enable co-development of cell and gene therapies with shared risk models to accelerate clinical advancement while controlling expenses.

Second, adopting a patient-centric development framework will strengthen real-world evidence generation, optimize trial design, and improve adherence. Tailoring protocols to accommodate home care administration and digital health support can differentiate offerings and align with evolving care delivery trends. In parallel, leveraging biomarkers to stratify patient populations will increase the probability of clinical success and support value-based pricing discussions.

Third, proactive engagement with regulatory agencies across key regions will facilitate alignment on accelerated approval pathways and post-market surveillance requirements. Companies should establish cross-functional regulatory task forces that integrate global policy insights, ensuring that development strategies are robust and adaptable.

By executing on these strategic imperatives, industry leaders can drive sustainable growth, enhance therapeutic impact, and maintain a competitive advantage in the rapidly evolving field of liver disease care.

The insights presented in this report are built upon a rigorous, multi-layered research methodology designed to ensure accuracy, relevance, and comprehensive coverage of the liver disease therapeutics landscape. Primary research forms the backbone of our analysis, incorporating in-depth interviews with key opinion leaders, clinical investigators, regulatory specialists, and senior executives within pharmaceutical and biotech companies.

Complementing these qualitative insights, secondary research draws from peer-reviewed journals, clinical trial registries, patent filings, and regulatory documents to validate pipeline developments and technology trends. Data from publicly available corporate reports, scientific conferences, and institutional repositories further enrich the contextual understanding of competitive dynamics.

Analytical frameworks, including SWOT assessments and PESTEL evaluations, have been applied to interpret strategic positioning, innovation drivers, and external influences such as tariff policies. Triangulation of qualitative and quantitative data ensures that findings are cross-verified and free from bias.

Finally, ongoing validation through expert workshops and scenario analyses enhances the robustness of conclusions and recommendations, providing stakeholders with a dependable foundation for strategic planning and investment decisions.

Synthesis of Key Findings and Strategic Reflections That Highlight the Pivotal Role of Innovative Therapies, Collaborative Efforts, and Policy Considerations in Advancing Liver Disease Treatment

This executive summary has synthesized the critical trends, tariff implications, segmentation nuances, regional drivers, and key organizational strategies that define the current and future state of liver disease therapeutics. The convergence of advanced biologic platforms, gene editing technologies, and patient-centric delivery models is reshaping treatment possibilities for conditions ranging from viral hepatitis to complex hepatocellular carcinomas.

By examining the cumulative impact of United States tariff measures, this report underscores the importance of resilient supply chain strategies and diversified manufacturing approaches. Segmentation analyses reveal distinct treatment pathways tailored to varied disease subtypes, therapeutic mechanisms, and delivery environments, while regional insights highlight the need for market-specific strategies informed by local healthcare infrastructures and regulatory landscapes.

Strategic recommendations emphasize the value of collaborative development models, patient-data integration, and proactive regulatory engagement. Together, these elements form a cohesive roadmap for stakeholders to navigate challenges, seize opportunities, and drive continued innovation in liver disease care.

In conclusion, the accelerated pace of scientific and policy evolution calls for decisive, informed action to translate research breakthroughs into tangible clinical benefits and deliver sustainable value to patients and healthcare systems alike.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Adoption of gene editing therapies for hereditary liver disorders with improving delivery vector safety profiles
• 5.2. Increasing prevalence of liver diseases drives therapeutic need
• 5.3. Integration of artificial intelligence platforms in optimizing nonalcoholic steatohepatitis clinical trials
• 5.4. Emerging regulatory pathways support cell-based therapeutic innovations for liver failure and cirrhosis
• 5.5. Growth of patient-centric remote monitoring solutions for early detection and management of hepatic complications
• 5.6. Surging venture capital investments fuel early-stage liver therapeutics
• 5.7. Collaborations between pharmaceutical companies and biotech firms to accelerate liver fibrosis drug candidate pipelines
• 5.8. Growth of combination small molecule and biologic therapies for advanced hepatocellular carcinoma
• 5.9. Government initiatives and public awareness drive early detection of liver diseases
• 5.10. Development of personalized medicine pipelines using multiomic biomarkers to predict patient responses in NASH trials

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Liver Diseases Therapeutics Market, by Disease Type

• 8.1. Introduction
• 8.2. Alcoholic Liver Disease
• 8.3. Hepatitis B
• 8.4. Hepatitis C
• 8.5. Liver Cancer
  • 8.5.1. Cholangiocarcinoma
  • 8.5.2. Hepatocellular Carcinoma
• 8.6. Non Alcoholic Lever Disease

9. Liver Diseases Therapeutics Market, by Therapy Type

• 9.1. Introduction
• 9.2. Biologic Immunotherapies
• 9.3. Cell-Based & Regenerative Therapy
• 9.4. Gene Therapy
• 9.5. Microbiome-Modulating Therapies
• 9.6. Small-Molecule Drugs

10. Liver Diseases Therapeutics Market, by Route Of Administration

• 10.1. Introduction
• 10.2. Intravenous
• 10.3. Oral
• 10.4. Subcutaneous

11. Liver Diseases Therapeutics Market, by Drug Class

• 11.1. Introduction
• 11.2. Antifibrotic
  • 11.2.1. Pirfenidone
  • 11.2.2. Simtuzumab
• 11.3. Antivirals
  • 11.3.1. Interferons
  • 11.3.2. NS5A Inhibitors
  • 11.3.3. NS5B Polymerase Inhibitors
  • 11.3.4. Nucleotide/Nucleoside Analogues
  • 11.3.5. Protease Inhibitors
• 11.4. Chemotherapeutic
• 11.5. Corticosteroids
• 11.6. Immunosuppressants
• 11.7. Monoclonal Antibody

12. Liver Diseases Therapeutics Market, by End User

• 12.1. Introduction
• 12.2. Clinic
• 12.3. Home Care Settings
• 12.4. Hospital

13. Liver Diseases Therapeutics Market, by Distribution Channel

• 13.1. Introduction
• 13.2. Hospital Pharmacy
• 13.3. Online Pharmacy
• 13.4. Retail Pharmacy

14. Americas Liver Diseases Therapeutics Market

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. Argentina

15. Europe, Middle East & Africa Liver Diseases Therapeutics Market

• 15.1. Introduction
• 15.2. United Kingdom
• 15.3. Germany
• 15.4. France
• 15.5. Russia
• 15.6. Italy
• 15.7. Spain
• 15.8. United Arab Emirates
• 15.9. Saudi Arabia
• 15.10. South Africa
• 15.11. Denmark
• 15.12. Netherlands
• 15.13. Qatar
• 15.14. Finland
• 15.15. Sweden
• 15.16. Nigeria
• 15.17. Egypt
• 15.18. Turkey
• 15.19. Israel
• 15.20. Norway
• 15.21. Poland
• 15.22. Switzerland

16. Asia-Pacific Liver Diseases Therapeutics Market

• 16.1. Introduction
• 16.2. China
• 16.3. India
• 16.4. Japan
• 16.5. Australia
• 16.6. South Korea
• 16.7. Indonesia
• 16.8. Thailand
• 16.9. Philippines
• 16.10. Malaysia
• 16.11. Singapore
• 16.12. Vietnam
• 16.13. Taiwan

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Gilead Sciences, Inc.
  • 17.3.2. AbbVie Inc.
  • 17.3.3. Merck & Co., Inc.
  • 17.3.4. Bristol-Myers Squibb Company
  • 17.3.5. Johnson & Johnson Services Inc.
  • 17.3.6. F. Hoffmann-La Roche Ltd.
  • 17.3.7. Pfizer Inc.
  • 17.3.8. Novartis AG
  • 17.3.9. GlaxoSmithKline plc
  • 17.3.10. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
  • 17.3.11. Sanofi SA
  • 17.3.12. Takeda Pharmaceutical Company Limited
  • 17.3.13. Vertex Pharmaceuticals Incorporated
  • 17.3.14. AstraZeneca PLC
  • 17.3.15. C. H. Boehringer Sohn AG & Co. KG
  • 17.3.16. Eli Lilly and Company
  • 17.3.17. Genfit S.A.
  • 17.3.18. Astellas Pharma Inc.
  • 17.3.19. Moderna, Inc.
  • 17.3.20. Alnylam Pharmaceuticals, Inc.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

• FIGURE 1. LIVER DISEASES THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 18. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 20. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 25. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 26. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 27. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHAI
• FIGURE 28. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHSTATISTICS
• FIGURE 29. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHCONTACTS
• FIGURE 30. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 73. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 75. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 77. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 79. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 81. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 83. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 85. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 87. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 89. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 91. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 93. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 95. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 96. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 97. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 99. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 101. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 103. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 105. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 107. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 108. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 109. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 110. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 111. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 112. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 113. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 115. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 116. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 117. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 118. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 119. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 120. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 121. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 122. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 123. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 124. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 125. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 126. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 127. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 128. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 129. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 130. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 131. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 132. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 133. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 134. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 135. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 136. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 137. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 138. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 139. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 140. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 141. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 142. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 143. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 144. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 145. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 146. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 147. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 148. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 149. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 150. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 151. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 152. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 153. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 154. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 155. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 156. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 157. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 158. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 159. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 160. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 161. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 162. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 163. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 164. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 165. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 166. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 167. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 168. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 169. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 170. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 171. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 172. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 173. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 174. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 175. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 176. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 177. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 178. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 179. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 180. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 181. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 182. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 183. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 184. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 185. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 186. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 187. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 188. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 189. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 190. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 191. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 192. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 193. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 194. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 195. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 196. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 197. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 198. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 199. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 200. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 201. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 202. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 203. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 204. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 205. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 206. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 227. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 228. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 230. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 232. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 234. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 236. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 238. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 240. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 242. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 243. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 244. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 245. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 246. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 247. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 248. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 249. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 250. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 251. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 252. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 253. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 254. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 255. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 256. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 257. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 258. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 259. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 260. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 261. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 262. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 263. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 264. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 265. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 266. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 267. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 268. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 269. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 270. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 271. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 272. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 273. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 274. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 275. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 276. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 277. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 278. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 279. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 280. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 281. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 282. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 283. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 284. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 285. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 286. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 287. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 288. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 289. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 290. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 291. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
• TABLE 292. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
• TABLE 293. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
• TABLE 294. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
• TABLE 295. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 296. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 297. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 298. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 299. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 300. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 301. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
• TABLE 302. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
• TABLE 303. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 304. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
• TABLE 305. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 306. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 307. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 308. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
• TABLE 309. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIF